Antares Pharma Announces FDA Approval Of XYOSTED For Testosterone Replacement

(RTTNews) - Antares Pharma, Inc. (ATRS) announced the approval of XYOSTED injection by the U.S. FDA. XYOSTED is the first FDA approved subcutaneous testosterone enanthate product for once-weekly, at-home self-administration with an easy-to-use, single dose, disposable QuickShot auto injector. XYOSTED is indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone.

"XYOSTED expands our branded portfolio of combination drug/device products and continues to highlight our passion and commitment to providing high quality therapies that improve patient care," said Robert Apple, CEO of the company.